Update from mevrometostat trial...good news!

[Maxone73]

From a "leaked" article...bah! But let's take it as real news, when it comes to "leaked" my mind always reads it like "stock market" but I want to be positive!

Mevrometostat has shown promising Phase I results in metastatic castration-resistant prostate cancer (mCRPC).

When combined with standard hormone therapy, it reduced disease progression by 50% and risk of death by 49% in pretreated patients.

Mevrometostat targets EZH2, an oncoprotein that promotes tumor growth by silencing tumor suppressor genes. While effective, the treatment had adverse effects such as diarrhea (78%) and appetite loss (58.5%).

Two Phase III trials (MEVPRO-1 and MEVPRO-2) will be carried out to further evaluate its safety and efficacy. If successful, this EZH2 inhibitor could become a new standard of care for prostate cancer.

prostatewarriors.com/2025/0...

[KocoPr]

combine that with MaaT013 microbiome treatment and the diarrhea and appetite loss would go away. Plus it would make it more effective.

[Maxone73]

This is old news, but "Results from a dose-expansion study (NCT03460977) showed promising activity and a manageable adverse-event profile for mevrometostat combined with enzalutamide in patients with CRPC who had evidence of cancer progression and had received prior abiraterone and/or enzalutamide. In his presentation, Dr. Agarwal described the study design of a phase 3 trial that aims to evaluate whether the addition of mevrometostat to enzalutamide can reverse anti-androgen resistance, thereby increasing the duration of clinical benefit in patients with mCRPC previously treated with abiraterone"

[Maxone73]

EDIT: Let me add some info I grabbed online (ok, I just had to wait since they will disclose the results today, but still...):

Mevro + Enza: 14.2 months rPFS

Enza alone: 6.2 months rPFS

We will see about OS.

I would be on average like gaining one extra year without progression...I would not mind that!